The $6.5bn price – biopharma’s biggest buyout of the year so far – shows how competitive the anti-FcRn space has become.
Biogen’s aducanumab filing is keenly awaited, as are clinical data from Sanofi, Bristol Myers Squibb, Lilly and others.
With data from a head-to-head trial against Cosentyx due soon, UCB’s bimekizumab seeks to enter a crowded psoriasis market.
A new mechanism for certain autoimmune conditions takes a big step forward with impressive pivotal data on Argenx’s efgartigimod.
170 commercial trials were suspended in March while new patient starts slumped 65% as the pandemic swept the globe. April could look even worse.